AstraZeneca unit draws line under Samsung dispute

AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

AstraZeneca prevails in GSK royalties row at UK High Court

6 April 2023 Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

Americas

Samsung Biologics faces suit from Amgen over bone biosimilars

15 August 2024 Amgen alleges infringement by proposed biosimilar versions of Prolia and XGEVA | Complaint accuses Samsung of failing to fully disclose biosimilar application and seeks injunction on bone-treatment products.

Big Pharma

Regeneron prevails in eye treatment dispute and immediately launches new suit

2 January 2024 District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.

More on this story

Big Pharma

AstraZeneca prevails in GSK royalties row at UK High Court

6 April 2023 Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

Americas

Samsung Biologics faces suit from Amgen over bone biosimilars

Big Pharma

Regeneron prevails in eye treatment dispute and immediately launches new suit

More on this story

Big Pharma

AstraZeneca prevails in GSK royalties row at UK High Court

6 April 2023 Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

Americas

Samsung Biologics faces suit from Amgen over bone biosimilars

Big Pharma

Regeneron prevails in eye treatment dispute and immediately launches new suit